IPO - LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Form Type: 424B4

Filing Date: 2025-04-11

Corporate Action: Ipo

Type: New

Accession Number: 000164117225003854

Filing Summary: Lixte Biotechnology Holdings, Inc. is offering a total of 467,393 shares of its common stock on a resale basis, along with additional shares that may be issued through the exercise of warrants. The offerings include 434,784 shares available through outstanding 2025 Warrants and 32,609 shares through the 2025 Placement Agent Warrants. The company will not receive proceeds from the sale of common stock by the selling stockholders but will benefit from cash payments upon the exercise of the warrants. The filing shows the last reported sales price of its common stock to be $1.22 on April 2, 2025, and emphasizes the potential risks associated with the investment. The company primarily focuses on developing cancer therapies, specifically through its lead compound LB-100, which has shown promise in treating various cancers. The document also mentions the potential for strategic partnerships in the future and highlights the company's patent strategy to enhance its clinical trials and protect intellectual property.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-04-09

Corporate Action: Ipo

Type: Update

Accession Number: 000164117225003403

Filing Summary: Lixte Biotechnology Holdings, Inc. filed Amendment No. 1 to its S-1 Registration Statement with the SEC on April 9, 2025. This filing corrects the hyperlink to the Company’s Annual Report for the fiscal year 2024 and updates filing dates and the signature page without making any other changes. The Company, based in Pasadena, CA, specializes in developing cancer therapies, particularly focusing on their lead compound LB-100, a protein phosphatase 2A inhibitor. LB-100 shows promise in enhancing the efficacy of existing cancer treatments such as chemotherapy and immunotherapy. The document notes that LB-100 has been tested in clinical trials for various cancers and is part of strategic planning to attract partnerships and additional capital. The registration includes offerings of common stock and warrants, and it follows an exempt private offering that occurred earlier in 2025. The prospectus emphasizes the risks associated with clinical development and the Company's dependence on additional funding. It concludes by underscoring the importance of potential strategic partnerships in advancing their combat against cancer. The Company is listed on The Nasdaq Capital Market under the symbol 'LIXT'.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: New

Accession Number: 000164117225002751

Filing Summary: Lixte Biotechnology Holdings, Inc. is submitting this registration statement under the Securities Act of 1933 for an initial public offering of common stock. The company is a clinical-stage biopharmaceutical firm focused on developing cancer therapies that target protein phosphatase 2A (PP2A). Their lead product candidate, LB-100, is currently undergoing clinical trials for various cancers including ovarian clear cell carcinoma and metastatic colon cancer. The company emphasizes its innovative approach and the enhanced effectiveness of LB-100 in combination with traditional cancer therapies. The initial offering is structured to include 467,393 shares of common stock and warrants that can convert to common stock, highlighting their commitment to expanding their pipeline and securing partnerships for development. The anticipated sales will begin pending SEC approval of this registration statement. The filing signifies a significant step for Lixte as they seek to enhance their capital resources and extend their research and development efforts.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: New

Accession Number: 000149315225006091

Filing Summary: Lixte Biotechnology Holdings, Inc. is offering 434,784 shares of its common stock at a price of $2.415 per share as outlined in a prospectus supplement filed on February 11, 2025. The offering is part of a registration statement under Rule 424(b)(5), and is in conjunction with a private placement of warrants to purchase an equivalent number of shares, with an exercise price of $2.29 per share. Concurrently, the placement agent, H.C. Wainwright & Co., LLC, will receive an 8.5% fee on proceeds. The delivery of shares is expected to occur around February 12, 2025, following the fulfilment of closing conditions. The past trading price for the common stock was recorded at $2.28 on February 10, 2025, with an aggregate market value for outstanding shares held by non-affiliates at $6,340,381. This prospectus highlights significant risks and financing concerns for the company, as they are in early-stage research without any revenue-generating operations, primarily relying on investments to fund clinical developments, particularly for their lead product candidate, LB-100, which is in various clinical trials.

Document Link: View Document